Revue Médicale Suisse
September 16, 2026
Rayan Nasserdine, Laura Xhymshiti, Anne-Charlotte Paporé et al.
Intravenous (IV) ketamine is a rapidly acting therapeutic option for the management of treatment-resistant depression and acute suicidal crisis. Unlike conventional antidepressants, its effects may occur within hours, allowing a rapid reduction in suicidal ideation and psychological distress. Its use remains specialized and requires hospital-based care with medical monitoring and a...
Revue Médicale Suisse
April 23, 2025
Louise Penzenstadler, Sandra Baudois, Alma Lingenberg et al.
Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their efficacy has been demonstrated in depression and anxiety, where they are particularly interesting because of their rapid and long-lasting effect. They could also be beneficial for addictions, post-traumatic stress, and obsessive-compulsive disorder. This...
Revue Médicale Suisse
February 12, 2025
Marco Solcà, Lola De Marcos Fuentes, Marie My Lien Rebetez et al.
Eating is essential to the survival of any living organism. However, beyond simple nutrition, eating is a source of pleasure that awakens a host of emotions and shapes our first relationships. In eating disorders, this vital process becomes a source of psychological distress, with somatic consequences and an impact on the functioning of the individual and his/her environment. Recently, new...
Revue Médicale Suisse
January 29, 2025
Yasser Khazaal, Maèva Flayelle, Joël Billieux et al.
Addiction medicine is confronting challenges brought about by changes in our modern world, including shifts in the drug market and the increasing digitalization of our environments. This article highlights some of these challenges and explores potential strategies to address them. The field is also advancing through robust research momentum in psychedelic-assisted psychotherapy. Additionally,...
Revue Médicale Suisse
April 3, 2024
Marion Waeber, Guglielmo Maria Pozzetti, Nicolas Donzé
Entheogens are a group of little-known psychoactive substances which consumption is nevertheless frequently mentioned in outpatient care and which can have harmful effects. This raises the question of appropriate management of their effects, as well as the treatment of any overdose. In this article, we focus on five of these substances, which are rarely described in the medical literature. At...
Revue Médicale Suisse
February 14, 2024
Aude Molinard-Chenu, Georgios Tsimploulis, Louise Penzenstadler et al.
Psychedelics are emerging as a therapeutic innovation in psychiatry and their use in chronic pain is worth exploring. In fact, they can modulate the serotonergic system, affecting central pain sensitization mechanisms. Ketamine, used for chronic analgesia, can lead to pain reduction, but additional studies are needed to assess its longterm effectiveness. "Classic" psychedelics are recently...
Revue Médicale Suisse
December 20, 2023
Amandine Schaller, Géraldine Bourquin, Indira Amorim Araujo et al.
Depression, anxiety and existential distress associated with terminal illness have a major impact on quality of life among palliative care patients. Psychedelics are emerging as catalysts for reflective, introspective and sometimes spiritual exploration as part of psychotherapy, with potentially rapid and long-lasting multiple beneficial effects. Psychedelic-assisted psychotherapy (PAP)...
Revue Médicale Suisse
August 23, 2023
Gabriel Thorens, Louise Penzenstadler, Federico Seragnoli et al.
2 citations
This article proposes 10 points considered essential on the ethics associated with the practice of psychotherapy assisted by psychedelics (PAP) : 1) respect of the legal framework (LStup) of the use of psychotropic drugs ; 2) adequately manage psychedelics (storage, production and safety) ; 3) announce adverse effects to the competent authority ; 4) guarantee a psychotherapeutic follow-up ; 5)...
Revue Médicale Suisse
June 21, 2023
Jelena Stanic, David Jackson-Perry, Corine Courvoisier et al.
Mindfulness meditation is a mind-body approach that helps to cope with psychological or physical symptoms such as pain. To date, this approach is still not widely available to patients in our French-speaking somatic clinical settings, despite its scientific validation. This article describes three mindfulness meditation programs delivered at Lausanne University Hospital (CHUV) to people living...
Revue Médicale Suisse
February 1, 2023
Vasileios Chytas, Paolo Cordera, Guido Bondolfi
Chronic pain requires an integrative approach. The prescription of opioids is increasing in Europe, including Switzerland, for the -treatment of chronic pain, despite their modest effectiveness. Mindfulness-based interventions have demonstrated their effectiveness in the management of chronic pain. The MORE program (Mindfulness-Oriented Recovery Enhancement) is an integrative therapy that uses...
Revue Médicale Suisse
2022
Marie-Thérèse Clerc, Marcus Rosenhagen-Lapoirie, Armin Von Gunten
Ketamine has demonstrated at a lower dose a robust and rapid antidepressant effect due to a mechanism of action different from conventional treatments. It is now included in several international recommendations on treatment-resistant depression. Ketamine may be used in both out- or in-patient settings, generally by way of intravenous or intranasal formulations provided the fulfillment of...